ClearPoint Neuro (NASDAQ:CLPT) posted its quarterly earnings data on Monday. The company reported ($0.13) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.15) by $0.02, MarketWatch Earnings reports. ClearPoint Neuro had a negative return on equity of 309.91% and a negative net margin of 55.55%.
Shares of CLPT traded up $0.27 during midday trading on Wednesday, reaching $17.93. The company had a trading volume of 10,010 shares, compared to its average volume of 431,024. ClearPoint Neuro has a 1-year low of $2.90 and a 1-year high of $31.29. The stock has a market cap of $367.80 million, a PE ratio of -40.50 and a beta of 1.15. The firm has a 50 day simple moving average of $20.20 and a 200-day simple moving average of $17.89. The company has a quick ratio of 4.47, a current ratio of 5.42 and a debt-to-equity ratio of 118.51.
CLPT has been the subject of several recent research reports. Lake Street Capital initiated coverage on ClearPoint Neuro in a research note on Wednesday, March 24th. They issued a “buy” rating and a $32.00 price objective for the company. B. Riley reissued a “buy” rating and issued a $38.00 price objective (up from $23.00) on shares of ClearPoint Neuro in a research note on Monday, February 22nd. Finally, Zacks Investment Research downgraded ClearPoint Neuro from a “buy” rating to a “hold” rating in a research note on Wednesday, May 5th.
ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system, a neuro-navigation system designed for instruments or devices designed to treat various neurological diseases and conditions, as well as for performing biopsies.
Further Reading: What is the operating income formula?
Receive News & Ratings for ClearPoint Neuro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ClearPoint Neuro and related companies with MarketBeat.com's FREE daily email newsletter.